 Cyclophosphamide ifosfamide combination neoadjuvant chemotherapy advanced nonsmall-cell lung cancer meta-analytic review Twenty-three patients resectable unresectable non-small-cell lung cancer stages IIIA IIIB neoadjuvant chemotherapy patients cycles preoperative chemotherapy agents i.v drug hematuria Six patients partial response patients underwent thoracotomy macroscopic residual disease Mean time progression whole group months Fifteen patients progression disease local metastases distant metastases chemotherapy cycles cyclophosphamide-ifosfamide doses patients hospitalization fever neutropenia nadirs two-alkylating non-cisplatin regimen cisplatin-based regimens ineffective trials